Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Dec 6;115(12):1515-1525.
doi: 10.1093/jnci/djad159.

Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial

Collaborators, Affiliations
Randomized Controlled Trial

Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial

Nicole E Billingy et al. J Natl Cancer Inst. .

Abstract

Background: Previous studies using patient-reported outcomes measures (PROMs) to monitor symptoms during and after (lung) cancer treatment used alerts that were sent to the health-care provider, although an approach in which patients receive alerts could be more clinically feasible. The primary aim of this study was to compare the effect of weekly PROM symptom monitoring via a reactive approach (patient receives alert) or active approach (health-care provider receives alert) with care as usual on health-related quality of life (HRQOL) at 15 weeks after start of treatment in lung cancer patients.

Methods: The SYMPRO-Lung trial is a multicenter randomized controlled trial using a stepped wedge design. Stage I-IV lung cancer patients in the reactive and active groups reported PROM symptoms weekly, which were linked to a common alerting algorithm. HRQOL was measured by the EORTC QLQ-C30 at baseline and after 15 weeks. Linear regression analyses and effect size estimates were used to assess mean QOL-C30 change scores between groups, accounting for confounding.

Results: A total of 515 patients were included (160 active group, 89 reactive group, 266 control group). No differences in HRQOL were observed between the reactive and active group (summary score: unstandardized beta [B] = 0.51, 95% confidence interval [CI] = -3.22 to 4.24, Cohen d effect size [ES] = 0.06; physical functioning: B = 0.25, 95% CI = -5.15 to 4.64, ES = 0.02). The combined intervention groups had statistically and clinically significantly better mean change scores on the summary score (B = 4.85, 95% CI = 1.96 to 7.73, ES = 0.57) and physical functioning (B = 7.00, 95% CI = 2.90 to 11.09, ES = 0.71) compared with the control group.

Conclusions: Weekly PRO symptom monitoring statistically and clinically significantly improves HRQOL in lung cancer patients. The logistically less intensive, reactive approach may be a better fit for implementation.

PubMed Disclaimer

Conflict of interest statement

Corina J.G. van den Hurk: IKNL received research funding from for-profit health care company AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Ipsen and Merck. All other authors have no conflicts of interest. The rest of the SYMPRO-Lung Consortium has nothing to declare.

Figures

Figure 1.
Figure 1.
Set of predefined conditions that prompted the web application to create an alert. PRO-CTCAE = Patient-Reported Outcomes–Common Terminology Criteria for Adverse Events.
Figure 2.
Figure 2.
CONSORT diagram of the Symptom Reporting with Patient-Reported Outcomes–Lung trial.
Figure 3.
Figure 3.
Proportion of patients with health-related quality of life changes at 15 weeks (T1) compared with baseline. For the clinically relevant change in physical functioning Cock et al. (33) guidelines for within-group changes were used: improvements: medium >7, small 7-2; no difference or trivial 2 to -5; deteriorations: small -5 to -10, medium -10 to -17, large <-17. P values were calculated using Pearson χ2 tests comparing the control group vs the intervention group.

Comment in

References

    1. Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. - PubMed
    1. National Cancer Institute Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version. https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq#_.... Accessed March 17, 2022.
    1. Cooley ME. Symptoms in adults with lung cancer. A systematic research review. J Pain Symptom Manage. 2000;19(2):137-153. - PubMed
    1. Basch E, Jia X, Heller G, et al.Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101(23):1624-1632. - PMC - PubMed
    1. Burkhart PV, Sabate E.. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh. 2003;35(3):207. - PubMed

Publication types